KindlyMD (NASDAQ:NAKA – Get Free Report) had its target price cut by B. Riley Financial from $13.00 to $10.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial‘s target price suggests a potential upside of 100.00% from the company’s previous close.
A number of other research analysts also recently weighed in on the stock. Wall Street Zen upgraded shares of KindlyMD from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a research note on Wednesday, November 4th. Finally, TD Cowen raised their target price on KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $19.00.
Check Out Our Latest Research Report on KindlyMD
KindlyMD Stock Performance
NAKA opened at $5.00 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.23 and a quick ratio of 0.23. The firm has a fifty day moving average price of $7.87 and a 200 day moving average price of $7.52. KindlyMD has a 1 year low of $3.33 and a 1 year high of $25.22. The stock has a market cap of $91.73 million, a P/E ratio of -0.33 and a beta of 16.03.
KindlyMD (NASDAQ:NAKA – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported $4.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $4.56. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 73.53%. The firm had revenue of ($1.93) million for the quarter. Equities research analysts anticipate that KindlyMD will post -12.94 earnings per share for the current year.
Insider Buying and Selling at KindlyMD
In related news, CEO David F. Bailey purchased 32,134 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were purchased at an average cost of $5.59 per share, with a total value of $179,629.06. Following the purchase, the chief executive officer owned 32,134 shares of the company’s stock, valued at $179,629.06. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have bought 41,904 shares of company stock worth $235,231. 24.08% of the stock is owned by corporate insiders.
About KindlyMD
KindlyMD is a Utah-based healthcare company that provides outpatient medical services, with a focus on integrated care. Its offerings include primary care, behavioral health and treatment for substance use disorders, along with care coordination intended to connect patients with appropriate services. The company serves patients through clinics in Utah and has emphasized care for people with complex or ongoing health needs. KindlyMD combined with Nakamoto Holdings in 2025; the resulting company trades on Nasdaq under the symbol NAKA.
Further Reading
- Five stocks we like better than KindlyMD
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for KindlyMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KindlyMD and related companies with MarketBeat.com's FREE daily email newsletter.
